Company Overview of Quanterix Corporation
Quanterix Corporation develops and provides ultra-sensitive diagnostic platform for measuring individual proteins. The company offers Single Molecule Array technology that enables the detection and quantification of biomarkers in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more; assay kits; and consumables. Its products are used in life science research, oncology, neurology, inflammatory disease, and infectious disease applications. Quanterix Corporation was formerly known as Digital Genomics Inc. and changed its name to Quanterix Corporation in August 2007. The company was founded in 2007 and is based in Lexington, Massachusetts.
13 Hartwell Avenue
Lexington, MA 02421
Founded in 2007
Key Executives for Quanterix Corporation
Executive Chairman and Chief Executive Officer
Co-Founder, Chairman of Scientific Advisory Board and Director
Chief Financial Officer and Vice President of Finance & Administration
Chief Technology Officer and Vice President of Research
Compensation as of Fiscal Year 2015.
Quanterix Corporation Key Developments
Quanterix Corporation Launches Next Generation Simoa 2.0 Ultrasensitive Immunoassay Platform
Oct 28 15
Quanterix Corporation announced the launch of Simoa 2.0, its next-generation ultrasensitive immunoassay platform. The Simoa 2.0 improvements will be available to all current Quanterix customers with a simple upgrade procedure and will be offered at no cost to ensure all users can benefit from the upgrades without any additional investment or interruption of their research. The upgrade includes numerous hardware and software advances and a comprehensive training program to ensure customers benefit from the many new features and capabilities. A number of beta customers around the world have already adopted Simoa 2.0 over the last few months and reported remarkable improvements in assay robustness, overall performace, reliability and ease of use.
Quanterix Corporation Seeks An IPO
Jul 8 15
Quanterix Corporation is planning to go public through initial public offering (IPO). Quanterix have begun conversations with investors on plotting an IPO. Kevin Hrusovsky, Chief Executive Officer of Quanterix said, "We’ll be doing that as part of our build out to become a public company. I would predict that we’ll be ready to do an IPO as early as early next year."
Quanterix Corporation Announces Commercial Availability of its Multiplex Panels and Homebrew Kits for Biomarker Discovery and Validation
Jun 9 15
Quanterix Corporation announced commercial availability of its multiplex panels, providing users with the ability to develop their own multiplex assays using the company’s ultra-sensitive Simoa technology. This allows users to achieve similar sensitivity with each marker in a multiplex panel as they would if they were to test individual assays. The company has also developed a convenient multiplex homebrew kit, allowing customers to use their own antibody pairs to develop custom multiplex Simoa panels, providing unlimited flexibility and significant cost savings. Researchers and clinicians want the ability to test for several different biomarkers on a small sample, making it possible to consider alternative, less invasive samples than the traditional blood test. The company's menu of Simoa assay kits has been growing rapidly and has now reached 30 assays, including markers for oncology, cardiology, neurology, infectious disease and inflammatory disease, all of which allow researchers to measure the associated biomarkers at levels that were impossible to measure until now. The first commercially available multiplex kits are 3-plex panels of cytokines, which are very useful for measuring inflammatory response across a wide range of conditions. These new panels are composed of individual cytokines that have been most popular with Simoa customers over the past year in singleplex format. The normal healthy range for many cytokines is close to the limit of detection of conventional immunoassay measurement techniques. Because of this, the sensitivity provided by Simoa allows researchers to measure both healthy and sick subjects with confidence, leading to a significant increase in demand for Simoa cytokine assays over the past year.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|